A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer

M. J. Moore; C. Erlichman; L. Kaizer; S. Fine

A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer

M. J. Moore, C. Erlichman, L. Kaizer, S. Fine

Medical Oncology

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m² and LV 20 mg/m² by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m² s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.

Original language	English (US)
Pages (from-to)	555-557
Number of pages	3
Journal	Anti-cancer drugs
Volume	4
Issue number	5
State	Published - Jan 1 1993

Keywords

5-Fluorouracil
Interferon
Leucovorin
Pancreatic cancer

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)
Cancer Research

Cite this

@article{6e15b3aee59f49f9b7f9de0611e73207,

title = "A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer",

abstract = "Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m2 s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.",

keywords = "5-Fluorouracil, Interferon, Leucovorin, Pancreatic cancer",

author = "Moore, {M. J.} and C. Erlichman and L. Kaizer and S. Fine",

year = "1993",

month = jan,

day = "1",

language = "English (US)",

volume = "4",

pages = "555--557",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer

AU - Moore, M. J.

AU - Erlichman, C.

AU - Kaizer, L.

AU - Fine, S.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m2 s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.

AB - Increased activity against colorectal cancer by 5-fluorouracil (5-Fu) modulation with leucovorin (LV) and/or interferon (IFN) has been reported. In this study 22 patients with measurable advanced pancreatic cancer received 5-Fu 375 mg/m2 and LV 20 mg/m2 by i.v. bolus daily x5 every 28 days plus IFN-α 3 million units/m2 s.c. There were three out of 21 (14%) responses lasting from 4 to 8 months. Sixteen patients (73%) had one or more episodes of grade 3 or greater toxicity (stomatitis, diarrhea or fatigue). While this combination has some activity against pancreatic cancer, its toxicity limits its potential as a palliative treatment.

KW - 5-Fluorouracil

KW - Interferon

KW - Leucovorin

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0027432954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027432954&partnerID=8YFLogxK

M3 - Article

C2 - 8292812

AN - SCOPUS:0027432954

SN - 0959-4973

VL - 4

SP - 555

EP - 557

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 5

ER -

A phase II study of 5-fluorouracil, leucovorin and interferon-α in advanced pancreatic cancer

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this